KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Sales for 18 consecutive years, with 0.18% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales rose 78.0% year-over-year to 0.18%; the TTM value through Mar 2026 reached 0.13%, up 26.0%, while the annual FY2025 figure was 0.08%, 21.0% up from the prior year.
  • Return on Sales hit 0.18% in Q1 2026 for Alnylam Pharmaceuticals, up from 0.1% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.23% in Q3 2025 and bottomed at 1.54% in Q3 2022.
  • Average Return on Sales over 5 years is 0.4%, with a median of 0.22% recorded in 2024.
  • Year-over-year, Return on Sales soared 173bps in 2023 and then plummeted -47bps in 2025.
  • Alnylam Pharmaceuticals' Return on Sales stood at 0.62% in 2022, then skyrocketed by 49bps to 0.31% in 2023, then surged by 55bps to 0.14% in 2024, then surged by 172bps to 0.1% in 2025, then surged by 74bps to 0.18% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.18%, 0.1%, and 0.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.